AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Special Article
February 23, 2022
Free Access

Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]
A Report of the AAN Guidelines Subcommittee

This article has a related notice.
VIEW NOTICE
Gregory S. Day, MD, MSc https://orcid.org/0000-0001-5133-5538, Nikolaos Scarmeas, MD, PhD, Richard Dubinsky, MD, MPH, Katherine Coerver, MD, PhD, Anitra Mostacero, Brooks West, Scott R. Wessels, MPS, ELS, and Melissa J. Armstrong, MD, MScAuthors Info & Affiliations
April 12, 2022 issue
98 (15) 619-631
https://doi.org/10.1212/WNL.0000000000200176
Letters to the Editor
Track CitationsAdd to favorites
full text
This guideline is retired. The recommendations and conclusions are no longer considered valid and no longer supported by the AAN. Retired guidelines should be used for historical reference only. Please see AAN current guidelines here.

Information & Authors

Information

Published In

Neurology®
Volume 98 • Number 15 • April 12, 2022
Pages: 619-631
PubMed: 35197360

Copyright

© 2022 American Academy of Neurology.

Publication History

Received: October 27, 2021
Accepted: January 25, 2022
Published online: February 23, 2022
Published in issue: April 12, 2022

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

Gregory S. Day, MD, MSc https://orcid.org/0000-0001-5133-5538
From the Department of Neurology (G.S.D.), Mayo Clinic, Jacksonville, FL; National and Kapodistrian University of Athens (N.S.), Greece; Columbia University (N.S.), New York, NY; University of Kansas Medical Center (R.D.), Kansas City; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Patient Representative (A.M.), San Antonio, TX; Care Partner Representative (B.W.), Telluride, CO; American Academy of Neurology (S.R.W.), Minneapolis, MN; and Department of Neurology (M.J.A.), University of Florida, Gainesville.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
<br>Continuing Education Company, Honoraria + travel for CME <br>activities<br>
Editorial Boards:
1.
<br>1. DynaMed, EBSCO; ad-hoc Dementia Topic Editor for online <br>evidence-based medicine resource; 2016-ongoing.<br>2. Associate Editor, Journal of Alzheimer's Disease<br>3. Level of Evidence Rater, Neurology<br>
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
<br>1. Parabon Nanolabs, Inc (advice / support on NIH-funded <br>project).<br>
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
<br>1. Biogen: Involved in clinical trials of <br>anti-amyloid agents (no direct payments; research agreement <br>between sponsor and institution).<br>
Research Support, Government Entities:
1.
<br>1. NIH/NIA: K23AG064029, PI, 2019-2024<br>2. NIH/NIA: U01AG057195, site-PI, 2021-<br>3. NIH/NIA: U19AG032438, site-PI, 2021-<br>
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
<br>1. Chan Zuckerberg Foundation (Neurodegenerative Challenge <br>Network), CS-0000000472, Clinical PI, 2019-2022<br>2. Alzheimer's Association (Grant to promote diverse <br>recruitment in LEADS; PI, 2021-22)<br> Stock/Stock Options, Medical Equipment & Materials: <br>1) Hold stocks (>$10,000) in ANI Pharmaceuticals (a <br>generic pharmaceutical company; 2015 onward).<br>2) Parabon Nanolabs, Inc (stock options).<br>
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
<br>1. Barrow Law, consultant concerning legal proceedings, 2018-<br>2021<br> Signature: /Gregory S Day/ Date: 1-18-2022<br><br>
View all articles by this author
Nikolaos Scarmeas, MD, PhD
From the Department of Neurology (G.S.D.), Mayo Clinic, Jacksonville, FL; National and Kapodistrian University of Athens (N.S.), Greece; Columbia University (N.S.), New York, NY; University of Kansas Medical Center (R.D.), Kansas City; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Patient Representative (A.M.), San Antonio, TX; Care Partner Representative (B.W.), Telluride, CO; American Academy of Neurology (S.R.W.), Minneapolis, MN; and Department of Neurology (M.J.A.), University of Florida, Gainesville.
Disclosure
Scientific Advisory Boards:
1.
<br>(1)Non-profit entity (Albert Einstein College of<br>Medicine): Data Safety Monitoring Board chair for an NIH<br>funded clinical trial.<br>
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
<br>(1) Commercial entity NovoNordisc - local PI of a recruiting site at a phase III clinical trial for Alzheimer's Disease – unrelated to the submitted work - funding to Institution.<br> Signature: /NIKOLAOS SCARMEAS/ Date: 19th January 2022<br><br>
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Richard Dubinsky, MD, MPH
From the Department of Neurology (G.S.D.), Mayo Clinic, Jacksonville, FL; National and Kapodistrian University of Athens (N.S.), Greece; Columbia University (N.S.), New York, NY; University of Kansas Medical Center (R.D.), Kansas City; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Patient Representative (A.M.), San Antonio, TX; Care Partner Representative (B.W.), Telluride, CO; American Academy of Neurology (S.R.W.), Minneapolis, MN; and Department of Neurology (M.J.A.), University of Florida, Gainesville.
Disclosure
Scientific Advisory Boards:
1.
<br>Allergan Pharmaceuticals, Scientific Advisory board on <br>the treatment of cervical dystonia and chronic daily headache.<br>
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
<br>Allergan Pharamceuticals, Irvine, CA, travel and honoraria, last time in 2019<br>
Editorial Boards:
1.
<br>Neurology editorial board, classification of level of evidence team<br>
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
<br>Allergan Pharmaceuticals<br>
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
<br>ENROLL-HD Longitudinal natural history study of<br>Huntington's disease. B. Landwehrmeyer, PI, Funded by CHDI. 2015–present. Site Investigator<br><br>PROOF-HD, PRidopidine Outcome On Function in Huntington Disease, Prilenia, Site investigator<br><br>Sage Therapuetics: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants with Huntington's Disease PROTOCOL NUMBER: 718-CIH-201<br>
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
<br>Abbott Labs and Abbvie. Wife owns stock<br> Signature: Richard M. Dubinsky, MD, mPH Date: 1/20/2022<br><br>
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Katherine Coerver, MD, PhD
From the Department of Neurology (G.S.D.), Mayo Clinic, Jacksonville, FL; National and Kapodistrian University of Athens (N.S.), Greece; Columbia University (N.S.), New York, NY; University of Kansas Medical Center (R.D.), Kansas City; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Patient Representative (A.M.), San Antonio, TX; Care Partner Representative (B.W.), Telluride, CO; American Academy of Neurology (S.R.W.), Minneapolis, MN; and Department of Neurology (M.J.A.), University of Florida, Gainesville.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
<br>GE Healthcare (Consultant)<br> Signature: /Katherine A Coerver, MD, PhD/ Date: 01/20/2022<br><br>
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Anitra Mostacero
From the Department of Neurology (G.S.D.), Mayo Clinic, Jacksonville, FL; National and Kapodistrian University of Athens (N.S.), Greece; Columbia University (N.S.), New York, NY; University of Kansas Medical Center (R.D.), Kansas City; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Patient Representative (A.M.), San Antonio, TX; Care Partner Representative (B.W.), Telluride, CO; American Academy of Neurology (S.R.W.), Minneapolis, MN; and Department of Neurology (M.J.A.), University of Florida, Gainesville.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Brooks West
From the Department of Neurology (G.S.D.), Mayo Clinic, Jacksonville, FL; National and Kapodistrian University of Athens (N.S.), Greece; Columbia University (N.S.), New York, NY; University of Kansas Medical Center (R.D.), Kansas City; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Patient Representative (A.M.), San Antonio, TX; Care Partner Representative (B.W.), Telluride, CO; American Academy of Neurology (S.R.W.), Minneapolis, MN; and Department of Neurology (M.J.A.), University of Florida, Gainesville.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Scott R. Wessels, MPS, ELS
From the Department of Neurology (G.S.D.), Mayo Clinic, Jacksonville, FL; National and Kapodistrian University of Athens (N.S.), Greece; Columbia University (N.S.), New York, NY; University of Kansas Medical Center (R.D.), Kansas City; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Patient Representative (A.M.), San Antonio, TX; Care Partner Representative (B.W.), Telluride, CO; American Academy of Neurology (S.R.W.), Minneapolis, MN; and Department of Neurology (M.J.A.), University of Florida, Gainesville.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
<br>American Academy of Neurology, Guideline and Measure <br>Publication Program Manager, 2 years<br> Signature: /Scott Wessels/ Date: January 18, 2021<br><br>
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Melissa J. Armstrong, MD, MSc
From the Department of Neurology (G.S.D.), Mayo Clinic, Jacksonville, FL; National and Kapodistrian University of Athens (N.S.), Greece; Columbia University (N.S.), New York, NY; University of Kansas Medical Center (R.D.), Kansas City; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Patient Representative (A.M.), San Antonio, TX; Care Partner Representative (B.W.), Telluride, CO; American Academy of Neurology (S.R.W.), Minneapolis, MN; and Department of Neurology (M.J.A.), University of Florida, Gainesville.
Disclosure
Scientific Advisory Boards:
1.
<br>(1) Alzheimer's Clinical Trial Consortium/Alzheimer's <br>Therapeutic Research Institute (DSMB)<br>(2) Alzheimer's Disease Cooperative Study (DSMB)<br>
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
<br>(1) American Academy of Neurology, travel to guideline <br>subcommittee meetings<br>
Editorial Boards:
1.
<br>(1) Neurology, Level of Evidence Editorial Board, 2012-<br>current<br>
Patents:
1.
NONE
Publishing Royalties:
1.
<br>(1) Parkinson's Disease: Improving Patient Care, Oxford <br>University Press, 2014<br>
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
<br>(1) American Academy of Neurology Evidence-Based Medicine <br>Methodology Consultant<br>
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
<br>(1) ARHQ, K08HS024159, PI, 2015-2020<br>(2) Florida Department of Health (20A08), co-PI, 2020-current<br>(3) NIA, P30AG047266, co-I, 2020-current<br>(4) NIA, R01AG068128, PI, 2020-current<br>
Research Support, Academic Entities:
1.
<br>(1) Mangurian Foundation (University of Florida pilot grant <br>mechanism) (2020)<br>
Research Support, Foundations and Societies:
1.
<br>(1) Lewy Body Dementia Association Research Center of <br>Excellence<br> Signature: /Melissa J. Armstrong/ Date: 1/18/2022
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author

Notes

Correspondence American Academy of Neurology [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Approved by the Guidelines Subcommittee on September 18, 2021, by the AAN Quality Committee on October 25, 2021, and by the AAN Institute Board of Directors on January 28, 2022.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Retirement of Guidelines, Neurology, 104, 9, (2025)./doi/10.1212/WNL.0000000000213572
    Abstract
    • Neel Vora,
    • Parth Patel,
    • Mohammed Dheyaa Marsool Marsool,
    • Ali Dheyaa Marsool Marsool,
    • Rayyan Sunasra,
    • Parva Ladani,
    • Shefali Pati,
    • Dhruvi Khoont,
    • Priyadarshi Prajjwal,
    • Raunak Ranjan,
    Atypical Alzheimer's dementia: Addressing the subtypes, epidemiology, atypical presentations, diagnostic biomarkers, and treatment updates, Disease-a-Month, 71, 5, (101863), (2025).https://doi.org/10.1016/j.disamonth.2025.101863
    Crossref
    • Mai Kuriyama,
    • Chu Fan Wang,
    • Tatsuya Nagase,
    • Youhei Sohma,
    • Motomu Kanai,
    • Yukiko Hori,
    • Taisuke Tomita,
    Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation, Neurotherapeutics, 22, 3, (e00548), (2025).https://doi.org/10.1016/j.neurot.2025.e00548
    Crossref
    • Jingjing Huang,
    • Xiaohong Long,
    • Chunyong Chen,
    A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system, Frontiers in Pharmacology, 16, (2025).https://doi.org/10.3389/fphar.2025.1522058
    Crossref
    • Jung M. Park,
    • Li-Huei Tsai,
    Innovations in noninvasive sensory stimulation treatments to combat Alzheimer’s disease, PLOS Biology, 23, 2, (e3003046), (2025).https://doi.org/10.1371/journal.pbio.3003046
    Crossref
    • Sakthi Priyadarshini,
    • Keshav Goyal,
    • Roopashree R,
    • Saurabh Gupta,
    • Aatreyi Roy,
    • Ritabrata Biswas,
    • Sandeep Patra,
    • Payal Chauhan,
    • Karan Wadhwa,
    • Govind Singh,
    • Mehnaz Kamal,
    • Danish Iqbal,
    • Mohammed Alsaweed,
    • Mohana Vamsi Nuli,
    • Mosleh Mohammad Abomughaid,
    • Abdulmajeed G. Almutary,
    • Jitendra Kumar Sinha,
    • Pooja Bansal,
    • Bindu Rani,
    • Chakshu Walia,
    • G. V. Sivaprasad,
    • Shreesh Ojha,
    • Vinod Kumar Nelson,
    • Niraj Kumar Jha,
    Polypharmacology and Neuroprotective Effects of Gingerol in Alzheimer’s Disease, Molecular Neurobiology, (2025).https://doi.org/10.1007/s12035-024-04484-y
    Crossref
    • Maia Zeni,
    • Maria Daniela Santi,
    • Florencia Arredondo,
    • Laura Reyes,
    • Manuela Bentura,
    • Diego Carvalho,
    • Mariana Peralta,
    • Maria Gabriela Ortega,
    • Juan A. Abin-Carriquiry,
    • Loreto Martínez-Gonzalez,
    • Juan Pablo Gambini,
    • Pablo Duarte,
    • Ana Martinez,
    • Ana Rey,
    • Javier Giglio,
    11C-Labeling of a Flavanone Extracted from a South American Native Species for Evaluation of Its Interaction with GSK-3β, Molecules, 30, 4, (874), (2025).https://doi.org/10.3390/molecules30040874
    Crossref
    • Jie Meng,
    • Peng Lei,
    Testing cognitive normal for Alzheimer's disease prediction, Journal of Neurochemistry, 169, 1, (2024).https://doi.org/10.1111/jnc.16272
    Crossref
    • Manuel Menendez-Gonzalez,
    Therapeutic Challenges Derived from the Interaction Among Apolipoprotein E, Cholesterol, and Amyloid in Alzheimer’s Disease, International Journal of Molecular Sciences, 25, 22, (12029), (2024).https://doi.org/10.3390/ijms252212029
    Crossref
    • Isabela Marie Fernandes Silva,
    • Graziella dos Reis Rosa Franco,
    • Vanessa Silva Gontijo,
    • Claudio Viegas,
    Protein kinases as therapeutic targets for Alzheimer’s disease: a brief review, Exploration of Neuroprotective Therapy, (411-441), (2024).https://doi.org/10.37349/ent.2024.00092
    Crossref
  11. See more

View Options

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

Figures

Tables

Media

Share

Share

Share article link

Share

View full text|Download PDF